developing animal models for in vivo target validation using shRNA, expressed from an adenovirus vector,says cellular and molecular biology director Helmuth van Es -for example, to target the synovium in a collageninduced model of arthritis.
High-throughput screening has revealed two bottlenecks in the target-discovery process, according to Sumit Chanda at the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. The first is the need to make RNAi screening in primary cell cultures as fast and efficient as in cell lines. The second is to translate in vitro results into animal models.
siRNA delivery to primary cells remains less efficient than in transformed cell lines, and not every primary cell type is amenable to lipid-based transfection.As an alternative, a few companies, including BTX in Holliston, Massachusetts, and Cyto Pulse Sciences in Columbia, Maryland, offer 96-well platebased electroporation. The GNF is developing high-throughput electroporation that would enable transfection with 20,000 oligonucleo-tides at a time, says Chanda, but this is not yet commercially available. And attempts to use vectors to deliver individual inhibitory RNAs to 20,000 wells at a time harbour significant technical and safety challenges, Chanda adds, including the need to achieve even titres of virus per well and to conduct all procedures to appropriate biosafety standards.
Down but not out
Several groups are tackling the second bottleneck -in vivo validation. Compared with the creation of gene knockouts in mice, which can take up to nine months, RNAi in animals can potentially produce answers within days or weeks, greatly speeding up the number of drug targets that can be validated in a given time. The often incomplete nature of RNAi -usually up to 90% knock-down -means that it may reflect more accurately the situation in human disease, where a disease-causing gene may be operating at suboptimal levels. It also mimics more closely the effect of a smallmolecule drug, which usually achieves only incomplete inhibition of its target.
Effective RNAi in vivo in animals could mean vast savings for the drug industry, says Martin Woodle of siRNA therapeutics company Intradigm in Rockville, Maryland. Traditionally it can cost from US$10 million to $50 million to identify a new small-molecule drug and go to the first tests in animals, making it expensive if drug targets that looked promising in vitro fail at this stage. Further savings will occur if the siRNA itself can be developed as the drug.
For research purposes, the GNF is trying to take RNAi into vertebrates with faster generation times than mice, such as zebrafish and chicks. But most research groups and companies are concentrating on developing the use of RNAi in mouse models of disease.
Getting it there
The key challenge for achieving effective RNAi in vivo is delivery to the desired organ and into the target cells, to ensure specificity and adequate dose. "RNAi will never leave the Petri dish until we solve the delivery problems," says William Pardridge, professor of medicine at the University of California, Los Angeles. But it's good news for the biotech sector that there is unlikely to be a single solution. "I think the delivery problem will be solved -either by delivery locally, into the local blood supply, or by targeting," says Judy Lieberman, a paediatrician at Harvard University's CBR Institute for Biomedical Research. "Viral vectors may make more sense for genetic diseases when you want long-term efficacy. There are so many possible indications that some delivery methods may be better than others."
One approach is to target the RNAi construct specifically at a tissue. Either the siRNA or the DNA encoding it is encased in a liposome or polymer coat, and ligands are incorporated into the coat that bind to cellsurface receptors on the target tissue, which rna interference technology feature
Alongside the optimism over RNA interference (RNAi) comes the inevitable question of whether it will fare better than previous RNA-based technologies -antisense and ribozymes -both in the laboratory and in the clinic. Many commentators are placing their bets on RNAi because it taps into a pre-existing control system within the cell and has the potential for greater potency, given that the same small interfering RNA (siRNA) molecules can recycle between different copies of messenger RNA. Single-stranded antisense molecules do not exist naturally, and each one acts only once to block translation of messenger RNA before being degraded. Ribozymes do cleave multiple copies of the same messenger RNA, but their potency remains in question, and there is, as yet, no sign of success as potential therapeutics.
"RNAi is what antisense never was. It's robust and reproducible, and it exists in nature," says Inder Verma of the Salk Institute for Biological Sciences in San Diego, California. RNAi is "much more active and effective than antisense and ribozymes", according to Martin Woodle of Intradigm in Rockville, Maryland.
Frank Bennett of Isis Pharmaceuticals in Carlsbad, California, disputes this, at least for in vitro use, saying that "by and large antisense and RNAi are equally potent in cell culture". For in vivo use, he asserts that RNAi has yet to be fully optimized to justify comparison with antisense. "We're keeping an open mind regarding the therapeutic potential of RNAi. It's too early to make predictions," he says.
Isis is so far the only company to have succeeded in getting an antisense drug licensed -Vitravene for the treatment of skin disease -and has other antisense products in clinical trials. In contrast, the company formerly known as Ribozyme Pharmaceuticals relaunched in 2003 as Sirna Therapeutics after its most promising antisense candidates proved ineffective in clinical trials. The RNAi technology breakthrough occurred at the right time, according to Nassim Usman, senior vice-president at Sirna.
Others point out the additional concerns that antisense molecules can trigger immune reactions, being larger and 'foreign' in composition, compared with siRNA, and can be toxic. But Bennett asserts that Isis has modified its antisense products to minimize these potential problems.
NeoPharm in Illinois is maintaining a stake in both approaches. While results from animals show the overall effectiveness of RNAi to be "very much better than with antisense", according to chief scientific officer Imran Ahmad, and to require a fivefold smaller dose, the company intends to compare its lipid-based delivery system for antisense and RNA side-by-side in the clinic.
